This proposal explored new drug treatment plans for pancreatic cancer. The mTOR protein kinase activates a signaling network that effects cell growth substantially. Research has shown that unregulated mTOR activity is linked with cancer progression. Therefore, finding inhibitors of mTOR could halter cell growth, particularly those of cancer cells. AZD2014 is a selective inhibitor of the mTOR complex. DNA damage stimulators Doxorubicin, Olaparib, and Trametinib in combination treatments can cause serious cell cycle arrest and death in pancreatic cancer cells. Experiments were completed with pancreatic cancer cells to observe the results of how effective the drug combinations were through p-AKT, total AKT, and Chk-1 signal detection and cell viability.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Kerns, Michelle Courtney

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042519-094637

Advisor

• Olsen, Carissa Lynn

Year

• 2019

Sponsor

• UMass Medical School

Date created

• 2019-04-25

Resource type

• Major Qualifying Project

Major

• Biochemistry

Rights statement

• In Copyright